NASDAQ:HRMY Harmony Biosciences (HRMY) Stock Price, News & Analysis → The biggest energy story ever? (From Porter & Company) (Ad) Free HRMY Stock Alerts $30.27 -0.64 (-2.07%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$29.62▼$30.7150-Day Range$28.85▼$33.6552-Week Range$18.61▼$39.26Volume783,153 shsAverage Volume396,711 shsMarket Capitalization$1.72 billionP/E Ratio14.28Dividend YieldN/APrice Target$40.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Harmony Biosciences alerts: Email Address Harmony Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside34.2% Upside$40.63 Price TargetShort InterestBearish21.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.68Based on 28 Articles This WeekInsider TradingSelling Shares$389,536 Sold Last QuarterProj. Earnings Growth31.33%From $3.00 to $3.94 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.07 out of 5 starsMedical Sector164th out of 927 stocksPharmaceutical Preparations Industry59th out of 415 stocks 3.3 Analyst's Opinion Consensus RatingHarmony Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, no hold ratings, and 2 sell ratings.Amount of Analyst CoverageHarmony Biosciences has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted21.01% of the float of Harmony Biosciences has been sold short.Short Interest Ratio / Days to CoverHarmony Biosciences has a short interest ratio ("days to cover") of 17.6, which indicates bearish sentiment.Change versus previous monthShort interest in Harmony Biosciences has recently increased by 1.73%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldHarmony Biosciences does not currently pay a dividend.Dividend GrowthHarmony Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HRMY. Previous Next 2.6 News and Social Media Coverage News SentimentHarmony Biosciences has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 28 news articles for Harmony Biosciences this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for HRMY on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harmony Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $389,536.00 in company stock.Percentage Held by Insiders30.80% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Harmony Biosciences are expected to grow by 31.33% in the coming year, from $3.00 to $3.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harmony Biosciences is 14.28, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 146.11.Price to Earnings Ratio vs. SectorThe P/E ratio of Harmony Biosciences is 14.28, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 260.31.Price to Earnings Growth RatioHarmony Biosciences has a PEG Ratio of 0.41. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHarmony Biosciences has a P/B Ratio of 3.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Harmony Biosciences Stock (NASDAQ:HRMY)Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Read More HRMY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HRMY Stock News HeadlinesMay 1, 2024 | finance.yahoo.comHarmony Biosciences Holdings Inc (HRMY) Q1 2024 Earnings Call Transcript Highlights: Strong ...May 1, 2024 | msn.comEasterly Government Properties, Inc. (NYSE:DEA) Q1 2024 Earnings Call TranscriptMay 2, 2024 | Priority Gold (Ad)Biden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...May 1, 2024 | americanbankingnews.comHarmony Biosciences' (HRMY) Buy Rating Reaffirmed at Needham & Company LLCApril 30, 2024 | msn.comRapidly Growing Harmony Biosciences Sees 30% Increase in Net Revenue, Boosts Growth Strategy With Rare Epilepsy Franchise AcquisitionApril 30, 2024 | bizjournals.comHarmony Biosciences shares soar on acquisition of New Jersey epilepsy drug developerApril 30, 2024 | fool.comHarmony Biosciences (HRMY) Q1 2024 Earnings Call TranscriptApril 30, 2024 | seekingalpha.comHarmony Biosciences: Company's Q1 Update Music To Investor Ears (Upgrade)May 2, 2024 | Priority Gold (Ad)Biden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...April 30, 2024 | marketwatch.comHarmony Biosciences Buys Epygenix Therapeutics For Initial $35 MillionApril 30, 2024 | marketwatch.comHarmony Biosciences Shares Rise After Earnings, AcquisitionApril 30, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), Moderna (MRNA) and Ionis Pharmaceuticals (IONS)April 30, 2024 | markets.businessinsider.comKey Takeaways From Harmony Biosciences Analyst RatingsApril 30, 2024 | msn.comHRMY Stock Earnings: Harmony Biosciences Beats EPS, Misses Revenue for Q1 2024April 30, 2024 | finance.yahoo.comHarmony Biosciences Exceeds Analyst Revenue Forecasts While Aligning with EPS Projections in Q1 2024April 30, 2024 | seekingalpha.comHarmony Biosciences Holdings, Inc. 2024 Q1 - Results - Earnings Call PresentationApril 30, 2024 | globenewswire.comHarmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare EpilepsyApril 30, 2024 | prnewswire.comHarmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS AssetsApril 29, 2024 | markets.businessinsider.comHarmony Biosciences earnings: here's what Wall Street expectsApril 29, 2024 | msn.comHarmony Biosciences Q1 2024 Earnings PreviewApril 28, 2024 | americanbankingnews.comHarmony Biosciences (HRMY) Set to Announce Earnings on TuesdayApril 22, 2024 | msn.comHarmony Biosciences to Unveil Q1 2024 Financial ResultsApril 22, 2024 | americanbankingnews.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Rating of "Moderate Buy" by AnalystsApril 16, 2024 | finance.yahoo.comHARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024April 15, 2024 | msn.comHarmony Biosciences Secures Exclusive Rights to Promising Narcolepsy TreatmentApril 12, 2024 | investing.comHarmony Biosciences secures rights to narcolepsy treatmentApril 11, 2024 | msn.comHarmony inks licensing deal for sleep disorder therapySee More Headlines Receive HRMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/30/2024Today5/02/2024Next Earnings (Estimated)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HRMY CUSIPN/A CIK1802665 Webwww.harmonybiosciences.com Phone484-539-9800FaxN/AEmployees246Year FoundedN/APrice Target and Rating Average Stock Price Target$40.63 High Stock Price Target$59.00 Low Stock Price Target$27.00 Potential Upside/Downside+34.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$2.12 Trailing P/E Ratio14.28 Forward P/E Ratio10.09 P/E Growth0.41Net Income$128.85 million Net Margins22.16% Pretax Margin29.79% Return on Equity27.49% Return on Assets16.83% Debt Debt-to-Equity Ratio0.38 Current Ratio2.75 Quick Ratio2.72 Sales & Book Value Annual Sales$582.02 million Price / Sales2.95 Cash Flow$2.70 per share Price / Cash Flow11.21 Book Value$7.97 per share Price / Book3.80Miscellaneous Outstanding Shares56,790,000Free Float39,299,000Market Cap$1.72 billion OptionableOptionable Beta0.73 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Jeffrey S. Aronin (Age 56)Founder & Non-Executive Chairman Comp: $19.6kDr. Jeffrey M. Dayno M.D. (Age 67)President, CEO & Director Comp: $762.15kMr. Jeffrey Dierks M.B.A. (Age 52)Executive VP & Chief Commercial Officer Comp: $662.1kMr. Andrew Serafin J.D. (Age 49)M.B.A., Executive VP & Chief Strategy Officer Comp: $605.42kMr. David BradshawHead of Technical OperationsLuis SanayHead of Investor RelationsMr. Christian UlrichGeneral Counsel & Corporate SecretaryMs. Tricia GloverChief Compliance OfficerMs. Audrey Murphy SPHRHead of Human ResourcesMs. Cate McCanlessHead of Corporate Affairs & Public PolicyMore ExecutivesKey CompetitorsSchrödingerNASDAQ:SDGRCatalyst PharmaceuticalsNASDAQ:CPRXSyndax PharmaceuticalsNASDAQ:SNDXAgios PharmaceuticalsNASDAQ:AGIOStructure TherapeuticsNASDAQ:GPCRView All CompetitorsInsiders & InstitutionsJanney Montgomery Scott LLCBought 2,465 shares on 5/1/2024Ownership: 0.053%Mirae Asset Global Investments Co. Ltd.Sold 3,610 shares on 5/1/2024Ownership: 0.023%Principal Financial Group Inc.Sold 5,994 shares on 4/29/2024Ownership: 0.338%China Universal Asset Management Co. Ltd.Bought 4,116 shares on 4/29/2024Ownership: 0.019%Yousif Capital Management LLCSold 1,405 shares on 4/26/2024Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions HRMY Stock Analysis - Frequently Asked Questions Should I buy or sell Harmony Biosciences stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Harmony Biosciences in the last twelve months. There are currently 2 sell ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HRMY shares. View HRMY analyst ratings or view top-rated stocks. What is Harmony Biosciences' stock price target for 2024? 8 brokerages have issued twelve-month target prices for Harmony Biosciences' stock. Their HRMY share price targets range from $27.00 to $59.00. On average, they predict the company's share price to reach $40.63 in the next twelve months. This suggests a possible upside of 34.2% from the stock's current price. View analysts price targets for HRMY or view top-rated stocks among Wall Street analysts. How have HRMY shares performed in 2024? Harmony Biosciences' stock was trading at $32.30 at the beginning of the year. Since then, HRMY stock has decreased by 6.3% and is now trading at $30.27. View the best growth stocks for 2024 here. When is Harmony Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024. View our HRMY earnings forecast. How were Harmony Biosciences' earnings last quarter? Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) posted its quarterly earnings results on Tuesday, April, 30th. The company reported $0.67 earnings per share for the quarter, beating analysts' consensus estimates of $0.60 by $0.07. The firm earned $154.62 million during the quarter, compared to analyst estimates of $154.10 million. Harmony Biosciences had a net margin of 22.16% and a trailing twelve-month return on equity of 27.49%. The company's quarterly revenue was up 29.8% compared to the same quarter last year. During the same period last year, the business earned $0.48 earnings per share. What ETFs hold Harmony Biosciences' stock? ETFs with the largest weight of Harmony Biosciences (NASDAQ:HRMY) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Janus Henderson Small Cap Growth Alpha ETF (JSML), Invesco S&P SmallCap 600 GARP ETF (GRPZ), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco S&P SmallCap Health Care ETF (PSCH) and Pacer US Small Cap Cash Cows 100 ETF (CALF).iShares U.S. Pharmaceuticals ETF (IHE). What guidance has Harmony Biosciences issued on next quarter's earnings? Harmony Biosciences updated its FY 2024 earnings guidance on Tuesday, April, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $700.0 million-$720.0 million, compared to the consensus revenue estimate of $710.2 million. What other stocks do shareholders of Harmony Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harmony Biosciences investors own include Advance Auto Parts (AAP), Advanced Micro Devices (AMD), Boeing (BA), Berry Global Group (BERY), Bunge Global (BG), Carrier Global (CARR), Commercial Metals (CMC), Canadian Solar (CSIQ), Deere & Company (DE) and Eastman Chemical (EMN). When did Harmony Biosciences IPO? Harmony Biosciences (HRMY) raised $101 million in an IPO on Wednesday, August 19th 2020. The company issued 4,700,000 shares at $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler acted as the underwriters for the IPO. Who are Harmony Biosciences' major shareholders? Harmony Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Principal Financial Group Inc. (0.34%), Paradiem LLC (0.17%), Hedeker Wealth LLC (0.14%), Rice Hall James & Associates LLC (0.10%), Allspring Global Investments Holdings LLC (0.06%) and Janney Montgomery Scott LLC (0.05%). Insiders that own company stock include Andreas Wicki, Jack Nielsen, Jeffrey Dierks, Jeffrey M Dayno, Jeffrey M Dayno, John C Jacobs and John C Jacobs. View institutional ownership trends. How do I buy shares of Harmony Biosciences? Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HRMY) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace😱 This phenomenon is smashing regular market gainsMillPubA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingForget Nvidia. This is the future of AIPorter & CompanyAI “wealth window” is closing June 25thParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
